Health Care · Pharmaceutical Preparations

MRVI MARAVAI LIFESCIENCES HOLDINGS, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 182323976 filings
Russell 2000

MRVI at a glance

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI, SEC CIK 1823239) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) reported revenue of $185.7 million (down 28.3% from FY2024) and a net loss of $130.8 million. Diluted EPS was -$0.90.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) shares worth $399.4 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$185.7M
−28.3% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
27 funds
$399.4M · −2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to previously disclosed risk factors since the December 31, 2025 Form 10-K

Management Discussion & Analysis

  • Revenue $45.9M, up 10.1% YoY from $41.6M
  • Gross margin 35.3% vs 13.6% YoY, net loss $24.0M vs $45.1M
  • Best segment TriLink: $28.4M, up 11.8%; Cygnus $17.5M, up 7.5%
  • Operating cash flow $17.7M vs $(34.8)M YoY; cash $73.0M at September 30
  • No further high-volume CleanCap COVID orders expected in 2026; 2027 binding orders absent

AI summary of the MRVI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced by Maravai LifeSciences
  • Full results, operating metrics and management commentary in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $45.9M, up 10.1% YoY, with TriLink up 11.8% and Cygnus up 7.5%
  • mRNA revenue rose 28%, while four Discovery customers transitioned to clinical-stage GMP, supporting future commercial demand
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $51.4M, up 8.5% year over year, led by TriLink growth of 11.5%
  • Adjusted EBITDA $8.7M versus $(10.4)M, signaling substantial operating leverage despite $21.6M net loss

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced by Maravai LifeSciences
  • Full earnings details available in Exhibit 99.1, including results and management commentary
Filed Jun 3, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $150M term loan plus $30M revolver, both maturing June 2, 2032
  • Refinancing funded with $98.5M cash, replacing and terminating the 2020 credit agreement

Item 7.01: Regulation FD Disclosure

  • No substantive Regulation FD disclosure provided in the excerpt
  • Text is a securities-law disclaimer, not operating or financial information

Item 1.02: Termination of a Material Definitive Agreement

  • Prior Credit Agreement terminated on June 2, 2026
  • All outstanding borrowings and accrued interest prepaid in full

AI summaries of MRVI 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MRVI

Don't miss the next MRVI filing

  • Alerts as it files. A push when MRVI files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MRVI, by share count.
  • Ask anything. An AI agent that reads every MRVI filing and answers with sources.

MRVI alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Brust BerndFNov 9, 2026$7.52
Asarpota RajeshFOct 30, 2026$8.46
Brust BerndFOct 8, 2026$7.43
Asarpota RajeshFSep 30, 2026$7.65
Brust BerndFSep 8, 2026$7.32
Asarpota RajeshFAug 31, 2026$7.68
Brust BerndFAug 10, 2026$6.23
Asarpota RajeshFJul 30, 2026$6.59

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$259.2M$185.7M
Gross Profit-$108.3M$34.0M
Operating Income--$235.6M-$215.3M
Net Income--$144.8M-$130.8M
Gross Margin-41.8%18.3%
Op. Margin--90.9%-115.9%
Net Margin--55.9%-70.4%
Balance Sheet
Total Assets-$1.0B$770.6M
Equity-$325.3M$212.4M
ROE--44.5%-61.6%
Per Share
EPS$-0.90$-1.05$-0.90
Cash Flow
Operating CF-$7.5M-$57.6M
CapEx$65.6M$29.7M$13.1M

Source: XBRL data in MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MRVI share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MRVI shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$399.4M
Q2 202629$299.7M
Q1 202628$106.4M
Q4 202524$118.8M
Q3 202525$103.6M
Q2 202527$94.8M
Q1 202523$75.0M
Q4 202419$164.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MRVI filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
10-QNov 5, 2026Analysis
8-KNov 4, 2026Analysis-
4Nov 2, 2026--
4Oct 9, 2026--
4Oct 1, 2026--
SC 13GSep 29, 2026-
4Sep 9, 2026--
4Sep 1, 2026--
4Aug 11, 2026--
10-QAug 7, 2026Analysis
8-KAug 6, 2026Analysis-
4Aug 3, 2026--
4Jul 10, 2026--
4Jul 1, 2026--
SC 13GJun 29, 2026-
SC 13GJun 23, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
8-KJun 3, 2026Analysis
8-KMay 29, 2026Analysis
4May 28, 2026-
4May 28, 2026-
4May 28, 2026-

Related Health Care companies

All Health Care →

MRVI SEC filings: frequently asked questions

Which institutions hold MRVI stock?

As of September 30, 2026, the largest MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) holders among the 13F filers tracked by SignalX were BlackRock ($80.9 million), Millennium Management ($58.4 million), Ameriprise Financial ($44.7 million), Vanguard Capital Management LLC ($40.2 million), Renaissance Technologies LLC ($30.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MRVI's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) reported revenue of $185.7 million (down 28.3% from FY2024) and a net loss of $130.8 million. Diluted EPS was -$0.90. The figures come from the XBRL data in the 10-K.

What did MRVI report in its latest 8-K?

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced by Maravai LifeSciences.

What are the latest MRVI SEC filings?

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 12, 2026.

What is MRVI's SEC CIK number?

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)'s SEC Central Index Key (CIK) is 1823239. EDGAR lists every MRVI filing under that number.

Ask anything about MRVI

The research agent reads MRVI's filings, financials, insider trades and 13F holders, then answers with sources.